The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

C-28 modified betulinic acid analogs are potent HIV entry inhibitors, while C-3 modified betulinic acid derivatives function by blocking virus maturation. [127] Among these bevirimat (Figure 23 ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

They graphically represent the life cycle of HIV-1, from the initial binding of the viral particle onto a host cell (Viral Entry), through insinuation into the host cell's nucleus to spark the ...

£35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts. A number of countries restrict the entry and/or residence of people with ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Although it is known that molecules with anti-HIV activity circulate in human blood, their identification has been hampered by difficulties in the purification and characterization of such compounds.

Entry inhibitors stop HIV from entering human cells. These include fusion inhibitors, CCR5 inhibitors and attachment inhibitors. In order to enter a host cell, HIV must bind to two separate receptors ...